Kornimate/medical-research-clean huggingface dataset:
oxygen partial pressure after breast cancer surgery

Conditions: Breast Cancer; Surgery-Complications; Hypoxia

Summary: hypoxia and reduced oxygen partial pressure is commonly occurring after abdominal surgery. this study aims to investigate whether similar changes also occur after breast cancer surgery. inclusion: 60 women undergoing breast cancer surgery. exclusion: dementia or cognitive impairment that makes it impossible to participate in the study. arterial blood gas and lung function are undertaken before surgery and the day after surgery

postoperative hypoxia complicates 30% - 50% of abdominal surgeries. people at particular risk for postoperative pulmonary complications including severe hypoxia are those who undergo abdominal surgery, emergency surgery or have a respiratory failure due to chronic lung disease. the cause of postoperative hypoxia and reduced lung function is unknown. previous studies report that arterial partial pressure (pao2) decreased by an average of 2 kilopascal after abdominal surgery, while carbon dioxide partial pressure (paco2) was unchanged and vital capacity decreased by 35%. the effect of breast cancer surgery on oxygen and carbon dioxide partial pressure and lung function has to the best of the investigators knowledge not been investigated. this study aims to investigate possible changes in oxygen partial pressure, carbon-dioxide partial pressure and vital capacity after breast cancer surgery. design: prospective cohort study participate in studies. method: blood gas measurements and lung function (vital capacity and fev1) the day before surgery, the day after surgery and at follow-up. power analysis: there is a need to investigate 27 patients if the mean (sd) difference is 0.5 (1) kilopascal. due to drop-outs the investigators calculate a need to include up to 60 patients.

Eligibility criteria:
inclusion criteria: • women scheduled for surgery because of breast cancer. exclusion criteria: • dementia or cognitive impairment that makes it impossible to participate in the study.

Keywords: breast cancer surgery postoperative hypoxia lung function
impact of the biological ratio on medical decision making in women suspected of preeclampsia

Conditions: Pre-Eclampsia

Summary: previous studies demonstrated that placental growth factor (pigf) and vascular endothelial growth factor (vegf) produced by trophoblast cells decreases during preeclampsia, whereas soluble fms-like tyrosine kinase-1 (sflt-1), an antiangiogenic factor, increases. the ratio sflt-1/plgf has a higher positive predictive value than the isolated measurement. a ratio under 38 exclude risk of imminent preeclampsia and allows to outpatient follow-up with a negative predictive value of 99.3%. a ratio equal or higher than 38 permits to direct high-risk patients towards hospitalization with a positive predictive value of 36.7% of preeclampsia at 4 weeks. these findings suggest that the ratio can be used to select more appropriately women needing hospitalization for suspected preeclampsia. this is a single-center prospective and observational study conducted from the 1rst of october 2019 to the 27th of january 2021, including pregnant women suspected of preeclampsia, above 24 weeks of gestation. values were measured using the elecsys sflt-1/plgf immunoassay ratio. the aim of the study is to observe the clinical decision regarding hospitalization, intensive patient monitoring, corticosteroid administration, and labor induction before and after knowing the ratio value


Eligibility criteria:
inclusion criteria: * pregnant patients over 24 weeks of amenorrhea * aged 18 and over * with suspicion of preeclampsia defined by the appearance of pregnancy-induced hypertension (≥ 140 in systolic and/or 90 mmhg in diastolic pressure over 2 measurements at 4 hours intervals) or proteinuria (≥ 0.3 g per 24 hours). * who systematically gave oral consent after submitting the information sheet exclusion criteria: * pregnant women with both hypertension and proteinuria because they already have a confirmed diagnosis of preeclampsia. * receiving antihypertensive treatment before pregnancy * or refusing to participate in the study the sflt-1/plgf ratio was measured only when clinically indicated as per the investigator's judgment.

Keywords: pre-eclampsia placental growth factor soluble fms-like tyrosine kinase medical care decision
treatment of nicotine dependence and acute depression

Conditions: Major Depressive Disorder; Nicotine Dependence

Summary: the purpose of this study is to assess the safety and feasibility of concurrent treatment of nicotine dependence (cigarette smoking) and acute depression. participants who meet dsm-iv criteria for both nicotine dependence and acute major depression will be given pharmacological treatment for both disorders at the same time, along with a brief behavioral intervention for smoking cessation.

the purpose of this study is to assess the safety and feasibility of concurrent treatment of nicotine dependence (cigarette smoking) and acute depression. participants who meet dsm-iv criteria for both nicotine dependence and acute major depression will be given pharmacological treatment for both disorders at the same time, along with a brief behavioral intervention for smoking cessation.

Eligibility criteria:
inclusion criteria: * age at least 18 at the beginning of the study * smoking at least 10 cigarettes a day (1/2 pack) * meets dsm-iv criteria for major depressive episode exclusion criteria: * currently pregnant * currently breastfeeding * currently diagnosed with a seizure disorder, liver disease, kidney disease, congestive heart failure or diabetes mellitis * history of a seizure, seizure disorder, significant head trauma or central nervous system tumor * family history of seizures * currently using intravenous drugs * currently using any drugs (marijuana, alcohol, cocaine, opiates, stimulants, etc.) on a daily basis * currently using any over-the-counter stimulants and anorectics (diet pills) * currently on fluoxetine (prozac), bupropion (wellbutrin, wellbutrin sr, wellbutrin xl) or any other antidepressants, monoamine oxidase inhibitors, antipsychotics, benzodiazepines, theophylline, systemic steroids or levodopa * currently on nrt or bupropion (zyban) * current or past diagnosis of anorexia nervosa * previous allergic response to fluoxetine, bupropion, or nrt * previous failed quit attempt using nrt and bupropion in combination * current suicidal ideation * current or past psychosis, mania/hypomania, or any other axis i or axis ii psychiatric diagnosis other than major depression and nicotine dependence
impact of telemonitoring for the management of side effects in patients with melanoma, lung or renal cancer, treated with immunotherapy combination of nivolumab and ipilimumab or adjuvant nivolumab monotherapy

Conditions: Melanoma; Lung Cancer; Renal Cancer

Summary: the ipilimumab and nivolumab combination is now part of the standard of care for the treatment of melanoma, renal and lung cancer patients. grade 3/4 adverse events (aes) occur in 30 to 60% of patients included in clinical trials. grade 3/4 aes are more frequently observed (50-60% of patients) in melanoma because ipilimumab is administrated at 3mg/kg in this population. among these aes, early detection of immune related aes is critical to an adequate medical management. in this context, dedicated tools for remote monitoring of these patients are crucial. the investigators developed within the immucare consortium a simplified medical questionnaire which is addressed weekly to the patients. this questionnaire along with an algorithm gives to the clinician regular feedback on their patients' general symptoms. the investigators herein want to evaluate in a randomized prospective trial the efficacy of this remote monitoring to reduce the time between the start of ae and the reporting to the medical team, which could lead to detect and treat earlier aes induced by nivolumab and ipilimumab in the melanoma, lung and renal cancer patients' population.


Eligibility criteria:
inclusion criteria: * age \> 18 years * patients diagnosed with melanoma, or lung cancer or renal cancer * patients starting a treatment with a combination of immunotherapy of nivolumab + ipilimumab (nb: patients who have already received immunotherapy in the past may be included) * patients comfortable with the use of digital tools and computing * patients who agree to participate to the telemonitoring and signed consent form exclusion criteria: * pregnant, parturient and lactating women * patients under legal protection measure or deprived of their liberty * patients not affiliated to a social security scheme (schemes such as the ame) or beneficiaries of a similar regime (foreign person, outside the eu)

Keywords: tele-monitoring nivolumab ipilimumab immunotherapy
transgender caregivers' and patients' representations of parenthood as part of a fertility preservation pathway

Conditions: Transgenderism; Fertility Issues

Summary: this research aims to understand the impact of fertility preservation consultation on transgender patients' projection and how the possibility of preserving gametes influences transgender people's transition paths, parenthood projects and health and health of transgender people through qualitative interviews. this research will also study the representations of members of medical and reproductive biology teams the possible use of stored gametes, and how these representations influence their clinical practice. clinical practice. to answer the research question, we plan to include 30 patients who have consulted for fertility preservation at the at the cecos of the tenon hospital, located in the 20th arrondissement of paris, and 20 members of the center's healthcare team. care team.

since the 2016 law, transgender people no longer need to provide "irreversible and medical proof of a physical transformation" in order to carry out a sex change at the civil registry, which puts an end to systematic sterilization and opens up the possibility of a hormonal-only transition. yet hormonal treatments can have an impact on the fertility of transgender people, compromising a subsequent project for parenthood. the reproductive biology department at tenon, where the research will take place, now offers self-conservation of female and male gametes before hormone replacement treatments are introduced, or during a therapeutic window. fertility preservation in transgender women relies primarily on sperm self-preservation. for transgender men, fertility preservation relies on cryopreservation of mature oocytes after ovarian stimulation. in addition to assessing the psychic impact of care in order to prevent potential deleterious effects, psycho-sexological consultation offers an opportunity to express the desire for a child, a desire often inhibited for a long time, as well as information on the possibilities of reuse. when it comes to research around the issue of fertility preservation for transgender people, there is often talk of problems concerning access to this care: the discriminatory practices of certain centers that refuse transgender people, the lack of training in transidentity issues for care teams, etc. the coercive weight of the law seems to be enough to evade the issue by moving it into the realm of legislation. and yet, in our clinical experience, the question of gamete reuse is a subject that merits research to determine the obstacles and levers for both caregivers and patients.

Eligibility criteria:
inclusion criteria: * any transgender person undergoing fertility preservation in the department * any member of the reproductive biology and medicine services team * aged 18 and over, with or without children * informed and having signed consent to participate in the research project exclusion criteria: * no social security * persons under guardianship

Keywords: transidentity preservation of fertility parenthood representations reproductive health
signal analysis for neurocritical patients

Conditions: Brain Injuries, Acute

Summary: the project uses big data analysis techniques such as wavelet transform and deep learning to analyze physiological signals from neurocritical patients and build a model to evaluate intracranial condition and to predict neurological outcome. by identification of correlations among these parameters and their trends, we may achieve early detection of anomalies and enhance the ability in judgement of current neurological condition and prediction of prognosis. by continuous input of the past and contemporary data in the icu, the model will be modified repeatedly and its accuracy improves as the model grows. the model can be used to recognize abnormalities earlier and provide a warning system. clinicians taking care of neurocritical patients can adjust their treatment policy and evaluate the outcome according to such system.


Eligibility criteria:
inclusion criteria: * age equal to or older than 20 years * neurocritical patients admitted to intensive care unit (icu), including but not limited to traumatic brain injury, hemorrhagic stroke, ischemic stroke, brain infection, brain tumor and acute hydrocephalus. * patients who have undergone cranial surgery and had intracranial pressure monitor inserted or external ventricular drainage. the central monitor of icu is able to collect the data continuously exclusion criteria: * age younger than 20 years. * continuous monitoring of intracranial pressure is not feasible.

Keywords: wavelet transform deep learning
effectiveness of ultrasound combine tens in treatment of upper trapezius myofascial pain

Conditions: Myofascial Pain Syndromes

Summary: to assess the effectiveness of therapeutic ultrasound combine transcutaneous electrical nerve stimulation (tens) and therapeutic ultrasound in treatment of myofascial pain syndrome in upper trapezius muscle measured by mean change between pre and post treatment of pressure pain threshold (ppt), patient's complaint in pain intensity and the number of total tablet usage of acetaminophen in both groups.

myofascial pain syndrome (mps) is one of the most common causes of musculoskeletal pain and can affect any skeletal muscles in the body.myofascial pain is not fatal condition but it can significant reduced quality of life and is a major cause of time lost from work. there are various treatments, which divided into invasive and non-invasive therapies. in the recent clinical practice, there is a new type of combine treatment unit which composes of electrotherapy and ultrasound therapy in one unit. however, there is no conclusive evidence for supports the effectiveness of this combine therapy compare with the conventional ultrasound in treatment of myofascial pain especially in aspect of pain relief.

Eligibility criteria:
inclusion criteria: * age \> 20 years old * clinical diagnosis of myofascial trigger point pain at upper trapezius muscle(s) persisted more than 1 week but less than 6 months before recruitment time, first or recurrence episodes * baseline vas more than or equal 4 at upper trapezius muscle exclusion criteria: * during the past 2 weeks had received injection or physical therapy at upper trapezius muscle or shoulder area * had experience of ultrasound combine transcutaneous electrical nerve stimulation (tens) * had history of accidence or severe trauma to shoulder region * had serious musculoskeletal condition that need surgical intervention such as acute shoulder subluxation, abnormal neurological examination * insensate skin or sensory impairment around shoulder area * skin infection at shoulder area * had contraindication for u/s such as cardiac pacemaker, implantation, malignancy in relevant area, bleeding disorder, acute inflammatory musculoskeletal disease, pregnancy, lactation * unable to communication * unable to complete treatment session and follow protocol

Keywords: myofascial pain syndrome therapeutic ultrasound combine therapy
acetylcholinesterase in postoperative delirium

Conditions: Delirium

Summary: the level of acetylcholinesterase is suspected to correlate with postoperative delirium. the investigators therefore score patients once preoperatively and twice postoperatively with the german version of the delirium-score nudesc (nursing delirium screening scale) and compare the results with the acetylcholinesterase activity, butyrylcholinesterase activity and the serum anticholinergic activity (saa) at corresponding time points.


Eligibility criteria:
inclusion criteria: * signed written informed consent * elective surgery exclusion criteria: * preexisting psychiatric or neurological disease * no surgery * reduced level of consciousness
half-dose flu vaccine study in healthy adults

Conditions: Influenza

Summary: it appears likely that there will be a delay and possibly a reduction in the amount of influenza vaccine available for the 2000-2001 influenza season. one possible way of increasing the availability of influenza vaccine for this year is to use a half-dose in healthy adults. the objective of this study is to determine if the immune system responds to a half-dose the same way it responds to a whole dose. this study will use the currently approved inactivated influenza vaccine in healthy adults ages 18 to 49 years old. if the immune response to the half-dose is not significantly different than the immune response generated to the whole dose, this could be a strategy to extend the amount of vaccine that could be available in this age group.

eligible subjects will be randomized to receive a single intramuscular injection of either a half-dose or a whole dose of a currently approved influenza virus vaccine in their arm. prior to vaccination, subjects will have one tube of blood drawn. subjects will be given a 3-day diary card to record any symptoms they may experience and asked to return for a second and final visit approximately 21 days following vaccination. a second blood draw will be done.

Eligibility criteria:
inclusion criteria: volunteers may be eligible for this trial if they: * are able to and have given informed consent. * are able to understand and comply with all study procedures and to complete study diary. * are aged 18 to 49 years. * are female, and are not pregnant. * are available for all study visits. exclusion criteria: volunteers will not be eligible for this trial if they: * are allergic to eggs or egg products. * have a current chronic medical condition for which influenza vaccine is normally recommended. * have received experimental vaccines or medications within 30 days of study entry. * have received parenteral immunoglobulin within 30 days of study entry.
porfiromycin used as an adjuvant to radiation therapy in postoperative head and neck cancer patients

Conditions: Head and Neck Neoplasms

Summary: determination of efficacy and safety of porfiromycin versus placebo as an adjuvant to radiotherapy in postoperative head and neck a cancer patients as well as assessment of population pharmacokinetic parameters.


Eligibility criteria:
inclusion criteria: * male or female postoperative radical neck surgery patients with histologically proven stage iii or iv (without distant metastases) epidermoid (squamous cell) carcinoma of the head and neck limited to the following locations as defined by the american joint commission (ajc): lip and oral cavity, pharynx, or larynx. * postoperative radical patients whose specimen had a) microscopic positive tumor cell margins (\< 2mm from surgical margin) or b) extranodal capsular spread (perineural-vascular embolization) or c) two or more positive nodes * postoperative radical neck patients must have received radiotherapy (rt). * performance status of ≥ 70 on the karnofsky performance score (kps) at screening. * patients ≥ 18 years of age * patients must have provided written informed consent prior to participation in the trial. * patients must have demonstrated an educational level and a degree of understanding such that they could communicate effectively with the investigator. exclusion criteria: * patients that received any prior chemotherapy including mitomycin-c or porfiromycin. * treatment with granulocyte, granulocyte-macrophage stimulating factor (g-csf, gm-csf) or interleukin-11 within 30 days prior to start of rt. * rt within the treatment field for any malignancy within the past five years. * patients who had any gross (visible or palpable) residual disease left after surgery. * patients who met any of the following clinical laboratory criteria upon screening: 1. granulocyte (neutrophil) count of \< 1,500/cubic millimeters (mm3) 2. platelets \< 75,000/mm3 3. prothrombin time (pt) and partial thromboplastin time (ptt) \> 1.5 times the upper limit of normal (uln) in seconds. * women who were pregnant or nursing. * women of childbearing potential who were unwilling to utilise a medically acceptable method of contraception (oral contraceptives, intrauterine devices, diaphragm or subdermal implants eg: norplant®). * other malignancies active within the past five years (other than basal or squamous cell carcinomas of the skin outside the planned radiation portals, or in situ carcinoma of the cervix). * the presence of more than one primary tumor or presence of distant metastases. * the presence of any other life-threatening illness, such a severe chronic lung, liver, or heart disease that would be expected to be fatal within five years, regardless of the patient's cancer status. * patients who participated in a clinical trial with another investigational drug or treatment 30 days prior to screening.
pregnancy and developmental outcomes after transfer of reportedly aneuploid or mosaic embryos

Conditions: Aneuploidy; Mosaicism; Pregnancy Outcome

Summary: to determine how often embryos reported to be abnormal by preimplantation genetic testing result in liveborn infants. to evaluate whether the pregnancies that result from these embryos are higher risk for complications and whether the resulting babies have higher risk for health or developmental issues in the first five years after birth.

genetic testing modality and results will be recorded pregnancy per transfer will be recorded patients in the study agree to provide medical records of their pregnancy. any genetic testing or fetal testing will be carefully reviewed and recorded by the study team. for patients with live births, pediatric records will be collected for up to 5 years. as well as surveys for developmental milestones. there is no financial compensation for study participants

Eligibility criteria:
inclusion criteria: * available aneuploid or mosaic embryos * no other acceptable embryos available * willing to travel to stanford for treatment * english language fluency exclusion criteria: * use of international donor eggs or sperm not tested according to fda guidelines. * living outside the united states * embryos with triploidy are not eligible for transfer in this protocol

Keywords: preimplantation genetic testing for aneuploidy preimplantation genetic screening embryo transfer mosaic aneuploid
treatment of dermatofibrosarcoma protuberans in patients 10 years and younger

Conditions: Dermatofibrosarcoma Protuberans

Summary: the purpose of this proposed study is to assess effectiveness of mohs micrographic surgery as a form of treatment for dermatofibrosarcoma protuberans in patients who are 10 years of age or younger through review of the patients at mayo clinic treated from 1988-2017, and to explore the challenges that providers face which may prevent them performing this potentially superior treatment. this study will provide a comparison of outcomes and recurrence rates in pediatric patients treated by mohs versus traditional excision.


Eligibility criteria:
must be 10 years of age or younger. must have biopsy proven dermatofibrosarcoma protuberans.